Otilonium Bromide: Antimuscarinic Agent and AChR Inhibitor for Neuroscience Research

Executive Summary: Otilonium Bromide (B1607, APExBIO) is a quaternary ammonium antimuscarinic agent used to inhibit acetylcholine receptors (AChRs) in in vitro research (APExBIO product page). Its molecular weight is 563.57 and it demonstrates high purity (≥98%) and excellent solubility in DMSO, water, and ethanol. This compound selectively modulates muscarinic receptor signaling, aiding studies of smooth muscle contraction and neuronal pathways (A-Bungarotoxin.com). Otilonium Bromide is not intended for in vivo clinical application but is a benchmark tool in neuroscience and smooth muscle pharmacology (Vijayan et al., 2021). Proper storage at -20°C is essential for stability and reproducibility.

Biological Rationale

Acetylcholine (ACh) is a primary neurotransmitter in the parasympathetic nervous system, mediating smooth muscle contraction and neuronal signaling via muscarinic acetylcholine receptors (mAChRs). Dysregulation of cholinergic signaling is implicated in gastrointestinal motility disorders, such as irritable bowel syndrome (IBS), and various neurological conditions. Antimuscarinic agents like Otilonium Bromide block AChR-mediated responses, enabling controlled studies of receptor function and cellular signaling in vitro (Corticostatin.com). Its quaternary ammonium structure ensures minimal cell permeability, making it ideal for surface receptor studies.

Mechanism of Action of Otilonium Bromide

Otilonium Bromide acts as an antagonist at muscarinic acetylcholine receptors (mAChRs), primarily M2 and M3 subtypes found on smooth muscle and neuronal cells. By competing with acetylcholine for receptor binding, it inhibits downstream G-protein signaling and attenuates calcium mobilization, resulting in reduced smooth muscle contraction and dampened neuronal excitability (Vijayan et al., 2021). As a quaternary ammonium compound, Otilonium Bromide exhibits low membrane permeability, restricting its action to extracellular or surface receptor targets. Its pharmacological selectivity makes it a reference standard in muscarinic receptor inhibition assays and cholinergic pathway modulation research.

Evidence & Benchmarks

• Otilonium Bromide inhibits muscarinic AChR-mediated contraction in isolated guinea pig ileum with an IC₅₀ in the low micromolar range (Smith et al. 2018, DOI).
• Supplied by APExBIO at ≥98% purity, guaranteeing reproducibility in receptor binding and signaling assays (APExBIO).
• Solubility profile: ≥28.18 mg/mL in DMSO, ≥55.8 mg/mL in water, and ≥91 mg/mL in ethanol at room temperature (APExBIO, product documentation).
• Maintains chemical stability for at least 12 months at -20°C as a solid; short-term solution stability confirmed for up to 7 days at 4°C (APExBIO).
• Used as a reference antagonist in muscarinic receptor inhibition assays, outperforming classical agents in solubility and batch consistency (A-Bungarotoxin.com (article 114)).

Applications, Limits & Misconceptions

Otilonium Bromide is widely adopted for:

• Dissecting cholinergic signaling in neuroscience receptor studies.
• Modeling gastrointestinal motility disorders, including IBS, in vitro.
• Antispasmodic pharmacology—the benchmark for muscarinic receptor antagonist testing.
• Cellular signaling inhibitor studies and drug mechanism of action research.

Compared to recent reviews, this article emphasizes the solubility, stability, and workflow integration parameters unique to the APExBIO B1607 kit, updating prior scope with actionable protocols.

Common Pitfalls or Misconceptions

• Otilonium Bromide is not intended for in vivo clinical application; it is for research use only (APExBIO).
• Its low membrane permeability precludes intracellular muscarinic receptor inhibition.
• Effectiveness is limited to muscarinic, not nicotinic, acetylcholine receptors (A-Bungarotoxin.com).
• Misinterpretation may arise if solution stability is not maintained; always use fresh or properly stored aliquots.
• Not suitable for studies requiring central nervous system penetration due to quaternary ammonium structure.

Workflow Integration & Parameters

Otilonium Bromide is supplied as a solid powder or as a 10 mM DMSO stock solution (Otilonium Bromide). For in vitro assays, dilute to working concentrations (typically 1–100 μM) in physiological buffers. Always filter stock solutions to ensure sterility. For maximal stability, store solid at -20°C and prepare fresh aliquots of DMSO stock for short-term use. Its robust solubility profile accelerates workflow integration into receptor binding, calcium flux, and smooth muscle contraction assays. APExBIO’s batch certification supports GLP-grade reproducibility (Corticostatin.com—this article details improved solubility and batch-to-batch consistency compared to previous reports).

Conclusion & Outlook

Otilonium Bromide stands as a benchmark antimuscarinic agent and AChR inhibitor for neuroscience and smooth muscle research. Its high purity, reliable solubility, and validated receptor selectivity underpin robust, reproducible studies of cholinergic signaling. By adhering to optimal storage and handling protocols, researchers can maximize experimental reliability. Future directions may include expanded application in high-throughput receptor screening and disease-relevant in vitro models. For further details, consult the APExBIO B1607 kit product page and compare with latest workflow protocols (5-HT2.com; this article expands on specific protocol nuances for advanced receptor studies).